Susquehanna International Group, LLP Spero Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 07, 2024	BUY	$1.35 - $1.79 $26,460 - $35,084	19,600 New	19,600 $33,000
Q4 2022 Feb 14, 2023	BUY	$1.55 - $2.12 $57,815 - $79,076	37,300 Added 134.17%	65,100 $112,000
Q3 2022 Nov 14, 2022	BUY	$0.68 - $2.2 $18,904 - $61,160	27,800 New	27,800 $56,000
Q4 2021 Feb 14, 2022	SELL	$13.09 - $18.77 $222,530 - $319,090	-17,000 Reduced 41.98%	23,500 $376,000
Q3 2021 Nov 15, 2021	BUY	$13.03 - $19.51 $144,633 - $216,561	11,100 Added 37.76%	40,500 $746,000
Q2 2021 Aug 11, 2021	BUY	$12.22 - $15.79 $158,860 - $205,270	13,000 Added 79.27%	29,400 $410,000
Q1 2021 May 17, 2021	SELL	$13.23 - $21.48 $137,592 - $223,392	-10,400 Reduced 38.81%	16,400 $241,000
Q4 2020 Feb 16, 2021	BUY	$11.65 - $22.07 $312,220 - $591,476	26,800 New	26,800 $520,000

13.9M

200

200

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $41.4M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.